Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
WuXi XDC Cayman, Inc. ( (HK:2268) ) has provided an update.
WuXi XDC Cayman Inc. has announced an extraordinary general meeting to approve a subscription agreement with WuXi Biologic (Cayman) Inc. The agreement involves issuing 24,134,000 new shares at HK$58.85 each, which is expected to enhance the company’s capital structure and support its growth initiatives.
The most recent analyst rating on (HK:2268) stock is a Buy with a HK$73.00 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.
More about WuXi XDC Cayman, Inc.
WuXi XDC Cayman Inc. is a company incorporated in the Cayman Islands, operating in the biotechnology sector. It focuses on developing and providing biologic technologies and services, with a market focus on innovative drug development and production.
Average Trading Volume: 6,963,270
Technical Sentiment Signal: Buy
Current Market Cap: HK$86.44B
For a thorough assessment of 2268 stock, go to TipRanks’ Stock Analysis page.